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Aims Implantable cardioverter defibrillator (ICD) therapy, which includes the risk of shocks, is considered the primary
culprit of reductions in patient reported outcomes (PROs; e.g. health status and distress), thereby negating the
role of underlying disease severity. We examined the relative influence of living with an ICD vs. congestive heart
failure (CHF) on PROs and compared (i) ICD patients without CHF (ICD only), (ii) CHF patients without an ICD
(CHF-only), and (iii) CHF patients with an ICD (ICD + CHF).
Methods
and results
Separate cohorts of ICD and CHF patients (N ¼ 435; 75% men) completed PROs at baseline, 6 and 12 months.
Groups differed on physical health status only at baseline (F(2,415) ¼ 7.15, P ¼ 0.001) and on anxiety at 12 months
(F(2,415) ¼ 4.04, P ¼ 0.01); ICD + CHF patients had the most impaired physical health status but the lowest
anxiety level followed by the ICD only and CHF only patients. Congestive heart failure only patients had the
most impaired mental health status and reported the highest level of anxiety as compared to the ICD only
(P, 0.001) and ICD + CHF groups (P ¼ 0.009), while the two latter groups did not differ. The effect sizes
ranged from very small (0.03) to moderate-large (0.69). Groups did not differ in depression scores.
Conclusion Congestive heart failure patients reported worse PROs as compared to ICD patients, although the magnitude of the
differences was relatively small. This suggests that the well being of patients is not necessarily negatively influenced by
the implantation of an ICD, and that underlying heart disease may have at least an equal if not greater influence on
PROs.
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Introduction
The implantable cardioverter defibrillator (ICD) comprises a
unique treatment option for patients at risk of sudden cardiac
death that is not paralleled by any other treatment for heart
disease. Besides dealing with their life-threatening condition, ICD
patients have to live with the risk of procedural and device-related
complications.1 These issues may have a negative impact on the
physical, social, and emotional functioning of patients.2 However,
ICD treatment seems to be well tolerated by the majority of
patients and ICD shocks only explain a marginal proportion of
the variance in patient reported outcomes (PROs) and changes
in PROs.3– 5 Moreover, the prevalence of symptoms of anxiety
and depression (5–63%) in ICD patients6 mirrors that found in
patients with congestive heart failure (CHF).7 This begs the ques-
tion whether it is the ICD placement in combination with fear of
ICD shocks or the underlying heart disease that influences PROs.
Except for the large-scale primary and secondary prevention
trials, e.g. the Defibrillators in Non-ischaemic Cardiomyopathy
Treatment Evaluation (DEFINITE), the Canadian Implantable De-
fibrillator Study (CIDS), and the Sudden Cardiac Death in Heart
Failure Trial (SCD-HeFT),4,8,9 a paucity of studies have examined
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the impact of ICD placement on PROs in order to attempt to dis-
entangle the impact of living with a device vs. the impact of the
underlying heart disease.10 –12 However, patients included in ran-
domized controlled trials do not necessarily represent patients
seen in ‘real world’ clinical practice.13 The few available observa-
tional studies have been based on relatively small sample sizes,
with the number of ICD patients ranging from 24 to 100, while
the number of patients in the comparison groups range from 25
to 50.10– 12
For physicians having to discuss the pros and cons of ICD im-
plantation with patients, it is important to have a true picture of
the impact of living with an ICD relative to heart disease on
PROs. Hence, in the current study, we compared three groups
(i) a cohort of ICD patients without CHF (ICD only), (ii) a
cohort of CHF patients without an ICD (CHF only), and (iii) a
cohort of ICD patients with CHF (ICD + CHF) on health status
and symptoms of anxiety and depression in an attempt to elucidate
the influence of the ICD vs. underlying heart disease on PROs,
using a prospective study design with a 12-month follow-up.
Methods
Study design and participants
The sample comprised consecutive CHF outpatients and/or ICD
patients recruited between August 2003 and September 2009 from
the Twee Steden Hospital (Tilburg and Waalwijk), St Elisabeth Hos-
pital (Tilburg), Amphia Hospital (Breda), ZorgSaam Ziekenhuis
(Zeeuws-Vlaanderen), and the Erasmus Medical Center (Rotterdam),
the Netherlands. The current study is based on two different
cohorts, one of ICD patients and the other of CHF patients. These
cohorts were derived from two separate prospective studies, one fo-
cusing on ICD patients and the other on CHF patients, and were
merged to test our post hoc retrospective hypothesis about potential
group differences. The CHF study recruited patients between 2006
and 2009, while the patients for the MIDAS (Mood and personality
as precipitants of arrhythmia in patients with an Implantable cardiover-
ter Defibrillator: A prospective Study) (ICD) were recruited between
2003 and 2009. Patients included in the Erasmus Medical Center
(recruited at the time of implantation) were all consecutive patients
implanted with a first-time ICD and participating in the ongoing
MIDAS study.14 All ICD patients were included around the time of im-
plantation ranging between 1 day prior to implant to 10 days post
implant. Inclusion criteria for the CHF-cohort15 outpatients were (i)
left ventricular ejection fraction (LVEF) ≤40%, (ii) age ≤80 years,
(iii) New York Heart Association (NYHA) functional class I– III, (iv)
no hospital admissions in the month prior to inclusion, and (v)
stable on oral medication during at least 1 month. Patients were
excluded in case of other life-threatening comorbidities (e.g. cancer),
presence of evident cognitive impairments, psychiatric comorbidity
(except for mood disorders), and/or insufficient understanding of the
Dutch language. Exclusion criteria for ICD patients were a life expect-
ancy ,1 year, a history of psychiatric illness other than affective/
anxiety disorders, on the waiting list for heart transplantation, or
with insufficient knowledge of the Dutch language. The study was con-
ducted according to the Helsinki Declaration and the protocols were
approved by the medical ethics committee of the participating hospi-
tals. All patients received written and oral information about the
study and signed an informed consent form prior to study
participation.
Measures
Socio-demographic and clinical variables
Information on socio-demographic variables were obtained either via
purpose-designed questions in the questionnaire or via the patients’
medical records. Demographic variables included gender, age, marital
status, and educational level. Clinical variables included aetiology
(ischaemic vs. non-ischaemic), ICD indication (primary vs. secondary),
NYHA functional class, LVEF, atrial fibrillation, diabetes mellitus, and
cardiac [i.e. diuretics, angiotensin-converting enzyme (ACE) inhibitors,
beta-blockers, and statins] and psychotropic medications.
Patient reported outcomes
Health status
The Dutch version of the Short-Form Health Survey 12 (SF-12) was
administered at inclusion, and at 6 and 12 months to assess generic
health status.16,17 The SF-12 measures overall physical and mental
health status, as indicated by the Physical Component Summary
(PCS) and the Mental Component Summary (MCS) scores, respective-
ly.18 All scale scores were standardized (score range 0–100), with
higher scores indicating better functioning.19 The SF-12 has been
shown to be a reliable and valid instrument.16
Symptoms of anxiety and depression
All patients completed the 14-item Hospital Anxiety and Depression
Scale (HADS) to assess symptoms of anxiety and depression at inclu-
sion and at 12 months follow-up.20,21 Items are answered on a 4-point
scale from 0 to 3, with a high score indicating more symptoms of
anxiety and depression, respectively. The dimensional structure and re-
liability of HADS has been confirmed in cardiac patients.22 A prede-
fined cut-off score of ≥8 on both subscales is used to indicate the
presence of probable clinical levels of symptoms of anxiety and depres-
sion, respectively.20
Statistical analyses
Prior to statistical analyses, missing items on questionnaires (1.1%) were
imputed using two-way imputation.23 To examine between-group differ-
ences, the x2 test (Fisher’s exact test when appropriate) was used for
dichotomous variables and Student’s t-test for independent samples
for continuous variables. Multivariable analysis of variance
(MANOVA) for repeated measures was performed to examine poten-
tial differences in mean scores between the three patient groups:
(i) ICD only, (ii) CHF only, and (iii) ICD + CHF (patients with CHF
and an ICD) on health status, and symptoms of anxiety and depression,
respectively. Patients with a CRT-D were excluded from analyses
because we wanted to rule out the potential confounding effect of
CRT-D on the chosen outcomes, given that CRT-D patients can
further be divided into responders and non-responders, which might
impact on the results. If a significant time by group interaction
(change over time differs for groups) was observed, analysis of variance
(ANOVA) was performed to compare the mean scores of the groups
at each time point. To adjust for potential confounders, we used multi-
variable analysis of covariance (MANCOVA) for repeated measures.
If the time by group interaction was significant we used analysis of co-
variance (ANCOVA) to compare the mean scores of the groups at
each time point. For every comparison the effect size has been calcu-
lated (Cohen’s d) in order to evaluate the clinical relevance of the
magnitude of the differences (0.2 small, 0.5 medium, 0.8 large) in
PROs between groups and not only the statistical significance.
A priori based on the literature, we had decided to include age,
gender, education, marital status, LVEF, NYHA functional class, aeti-
ology, diabetes, atrial fibrillation, diuretics, statins, beta-blockers,
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ACE-inhibitors, and use of psychotropic medication as covariates in
multivariable analyses. Left ventricular ejection fraction was added to
the model in secondary analyses because of the number of missing
values on this variable. Statistical analyses were performed using
SPSS for Windows 17.0 (SPSS Inc., Chicago, IL, USA). All tests were
two-tailed, and a,0.05 was used to indicate statistical significance.
To reduce the chance of Type 1 error (i.e. finding a significant result
when in fact there is none), we applied the Bonferroni correction to
the (M)AN(C)OVA’s by dividing the alpha by the number of per-
formed tests 0.05/4. Hence, a significance level of 0.01 was used to in-
dicate statistical significance for these analyses.
Results
Patient characteristics
Of 737 patients who were eligible to participate in the study, 162
patients refused (response rate ¼ 78%), 35 (4.7%) patients died
between baseline and 12 months follow-up, 51 (6.9%) were lost
to follow-up, and 54 (7.3%) patients had missing data on self-report
measures or clinical variables. Final analyses were based on 435
patients, divided into three groups: (i) ICD only patients (n ¼
188; 43.2%), (ii) CHF only (n ¼ 208; 47.8%), and (iii) ICD + CHF
(n ¼ 39; 9%). Patients who were excluded from analyses did not
differ systematically on baseline characteristics from included
patients (all Ps. 0.05; data not shown). The mean age of the
total sample was 61.73+ 11.72 years with 348 patients (80%)
being men. Patient baseline characteristics for the total sample
and stratified by group are shown in Table 1. Group differences
were observed in age, marital status, working status, LVEF,
NYHA class, diabetes, use of diuretics, statins, beta-blockers, and
psychotropic medication.
Health status
Unadjusted analyses
Multivariable analysis of variance for repeated measures showed a
significant time by group interaction for physical health status (i.e.
PCS) (F(2,432) ¼ 12.27, P ≤ 0.001) but not for mental health status
(i.e. MCS) (F(2,432) ¼ 1.71, P ¼ 0.15). The significant time by group
interaction for physical health status indicates that the mean score
evolved differently for the three groups during the 12-month
follow-up period. Due to the significant interaction, we performed
simple effects ANOVA, which showed that groups differed signifi-
cantly on physical health status at baseline (F(2,432) ¼ 15.92, P,
0.001), at 6 months (F(2,432) ¼ 11.82, P, 0.001), and at 12
months follow-up (F(2,432) ¼ 11.63, P, 0.001). At baseline, the
CHF only patients had the highest score followed by the ICD
only and the ICD + CHF patients. However, at 6 and 12
months, the ICD only patients had the highest score followed by
the CHF patients only, while the ICD + CHF patients reported
the poorest physical health status. For mental health status, the
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Table 1 Patient baseline characteristics for the total sample and stratified by groupa
Total (N 5 435) ICD only (N 5 188) CHF only (N5 208) ICD1 CHF (N5 39) P
Demographics
Age 61.7+11.7 57.5+12.5 66.8+8.4 54.9+11.9 0.0011
Gender (male) 348 (80.0) 150 (79.8) 165 (79.3) 33 (84.6) 0.75
Education (low) 305 (70.1) 52 (27.7) 68 (32.7) 10 (25.6) 0.46
Marital status (partner) 371 (85.3) 175 (94.6) 159 (76.4) 37 (94.9) ,0.0012
Working status (working) 128 (29.4) 85 (42.5) 34 (16.3) 9 (23.1) ,0.0013
Clinical variables
Secondary indication 98 (22.5) 92 (48.9) – 6 (15.4) –
LVEF,35%b 232 (53.3) 89 (73.6) 115 (55.3) 28 (90.3) ,0.0014
NYHA class III/IV 43 (9.9) 4 (2.1) 14 (6.8) 25 (61.4) ,0.0015
CAD 268 (61.6) 116 (61.7) 129 (62.0) 23 (59.0) 0.94
Diabetes 86 (19.8) 24 (13.3) 57 (20.4) 4 (10.3) 0.0016
Atrial fibrillation 99 (22.8) 38 (20.2) 52 (25.0) 9 (23.1) 0.53
Medication
Diuretics 224 (51.5) 67 (35.6) 126 (60.6) 31 (79.5) ,0.0017
Statins 276 (63.4) 108 (57.4) 146 (70.2) 22 (56.4) 0.028
Beta-blockers 319 (73.3) 142 (75.5) 143 (68.8) 34 (87.2) 0.049
ACE-inhibitors 275 (63.2) 115 (61.2) 130 (62.5) 30 (76.9) 0.17
Psychotropic medication 73 (16.8) 28 (15.0) 33 (15.9) 12 (30.8) 0.04910
aResults are presented as numbers (percentages) unless otherwise indicated.
bInformation on LVEF was only available in a subset of patients (n ¼ 360).
1–10Post hoc analyses (Tukey’s HSD test), significant differences observed: 1between ICD vs. CHF (P, 0.001) and CHF vs. ICD + CHF (P, 0.001); 2between ICD vs. CHF (P,
0.001) and CHF vs. ICD + CHF (P ¼ 0.005); 3between ICD vs. CHF (P, 0.001) and ICD vs. ICD + CHF (P ¼ 0.011); 4between ICD vs. CHF (P ¼ 0.002) and CHF vs. ICD +
CHF (P, 0.001); 5between ICD vs. ICD + CHF (P, 0.001) and CHF vs. ICD + CHF (P, 0.001); 6between ICD vs. CHF (P ¼ 0.001) and CHF vs. ICD + CHF (P ¼ 0.034);
7between ICD vs. CHF (P, 0.001) and ICD vs. ICD + CHF (P, 0.001); 8between ICD vs. CHF (P ¼ 0.023); 9between CHF vs. ICD + CHF (P ¼ 0.044); 10between ICD vs.
ICD + CHF (P ¼ 0.043)
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non-significant time by group (F(2,432) ¼ 1.71, P ¼ 0.15) interaction
indicated that group exerted a stable effect over time, with the
CHF only patients generally having the lowest score followed by
the ICD + CHF patients, and the ICD only patients reporting
the best mental health status (F(2,432) ¼ 16.83, P, .001). In
general, mental health status improved over time, as indicated by
a significant main effect for time (F(2,432) ¼ 17.51, P, 0.001).
Adjusted analyses
In adjusted analysis, a significant time by group interaction was still
observed for physical health status (F(2,415) ¼ 7.63, P, 0.001) but
not for mental health status (F(2,415) ¼ 0.76, P ¼ 0.55). Due to the
significant time by group interaction, simple effects ANCOVA was
performed for physical health status, which showed that the
groups had significantly different scores only at baseline
(F(2,415) ¼ 7.15, P ¼ 0.001), with the ICD + CHF patients having
the lowest scores followed by the ICD only and CHF only patients.
These differences were neither observed at 6 (F(2,415) ¼ 1.07, P ¼
0.35) nor at 12 months (F(2,415) ¼ 0.97, P ¼ 0.38) (Figure 1A). With
respect to mental health status, MANCOVA for repeated mea-
sures showed that the CHF only patients scored significantly
lower than the ICD only (P, 0.001), and the ICD + CHF patients
(P ¼ 0.009) at all time points. No significant difference was
observed between the ICD only and ICD + CHF only patients.
In general, mental health status tended to improve over time in
all groups, however, not significantly as indicated by a non-
significant main effect for time (F(2,415) ¼ 2.07, P ¼ 0.07)
(Figure 1B). Results did not change after additional adjustment for
LVEF (results not shown).
Anxiety and depressive symptoms
Unadjusted analyses
Anxiety and depressive symptoms were assessed at the time of in-
clusion and at 12 months follow-up. Multivariable analysis of vari-
ance for repeated measures showed a significant time by group
interaction for anxiety (F(2,432) ¼ 7.23, P ¼ 0.001) but not for de-
pression (F(2,432) ¼ 3.25, P ¼ 0.04), indicating that anxiety levels
across the three groups had a different evolution. Therefore, we
performed a simple effects ANOVA, which showed neither signifi-
cant differences between groups on anxiety at baseline (F(2,432) ¼
1.07, P ¼ 0.34) nor at 12 months (F(2,432) ¼ 1.98, P ¼ 0.14). With
respect to depression, no significant differences between groups
were observed (F(2,432) ¼ 3.39, P ¼ 0.02), with depression de-
creasing in all groups as indicated by a significant time main
effect (F(2,432) ¼ 7.19, P ¼ 0.008).
Adjusted analyses
In adjusted analysis, MANCOVA for repeated measures still
showed a significant time by group interaction for anxiety
(F(2,415) ¼ 8.22, P, 0.001) but not for depression (F(1,415) ¼
3.49, P ¼ 0.03). Focusing on anxiety, simple effects ANCOVA
showed no significant difference between groups at baseline
(F(2,415) ¼ 0.34, P ¼ 0.72). However, at 12 months follow-up
scores did differ between groups (F(2,415)¼ 4.04, P ¼ 0.01), with
the CHF only patients having the highest anxiety levels followed
by the ICD only patients. The ICD + CHF patients reported the
lowest anxiety levels (Figure 2A). No significant differences in de-
pression levels were observed between groups (F(2,415) ¼ 0.41,
P ¼ 0.67) (Figure 2B). Depression did not change significantly
over time, as indicated by the non-significant time effect
(F(2,415) ¼ 0.33, P ¼ 0.56). Adding LVEF as a covariate to these ana-
lyses did not alter the results (results not shown).
Effect size
In Table 2, the effect sizes for differences between groups are dis-
played. The effect size is a measure of the magnitude of the differ-
ences between groups. The effect sizes ranged from very small
(0.03) to moderate-large (0.69). As shown in Table 2, the differ-
ences were generally most prominent between the CHF and
ICD + CHF groups, showing higher MCS scores and lower
anxiety levels in the ICD + CHF group as compared to the CHF
only group. In adjusted analyses, the ICD-CHF group scored on
average 5 points higher on the MCS than the CHF group and 1
point lower on anxiety. Although there are no prespecified
cut-off scores to indicate severity (or clinically relevant difference
between groups) on the health status measures, the effect sizes
that were found in this study are in line with our expectations
and indicate that the implantation of an ICD after CHF diagnosis
does not necessarily have a negative influence on PROs.
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Figure 1 (A) Mean scores on the PCS stratified by group
(adjusted analysis). Scores can range between 0 and 100 (higher
scores indicating better functioning). (B) Mean scores on the
MCS score stratified by group (adjusted analysis). Scores can
range between 0 and 100 (higher scores indicating better
functioning).
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Concerning symptoms of anxiety and depression, all groups scored
on average below the clinical cut-off of 8 at all time points. Al-
though there were some differences in scores between groups,
this indicates that none of the groups were particularly more at
risk for clinical levels of distress than others.
Discussion
The objective of the current study was to compare health status
and the level of anxiety and depressive symptomatology in patients
with an ICD only vs. CHF only and ICD + CHF in order to eluci-
date the influence of the ICD placement vs. underlying heart
disease on PROs. Focusing on physical health status, significant dif-
ferences between groups were observed only at baseline, with the
CHF only group reporting the best health status followed by the
ICD only and ICD + CHF groups. With respect to mental health
status, differences were observed at baseline, 6, and 12 months,
with the CHF only group reporting significantly worse mental
health status as compared to the ICD only and ICD + CHF
groups. Statistically significant differences were observed in
anxiety only at 12 months follow-up. The CHF only group
reported the highest level of anxiety followed by the ICD only
and ICD + CHF groups. No significant differences were observed
between groups on depression.
The results of the current study show that there are differences
in health status and anxiety between groups at some but not
all time points. These differences were statistically significant,
but the magnitude of the differences was relatively small, and as
such the results do not warrant changes to clinical practice.
Overall, the results suggest that patients with an ICD are not ne-
cessarily worse off in terms of their well being and health status
than patients with CHF, despite the challenges of living with a
device which include ICD shocks and the risk of complications.
Rather the findings indicate that psychological distress and poor
health status are perhaps more related to disease severity than
to living with an ICD. These findings are in line with previous
studies in ICD patients, suggesting that patients are generally well
able to cope with their device, shock(s) and device advisory noti-
fications.5,24 In contrast, symptomatic CHF, as indicated by NYHA
functional class III– IV, seems to have a greater influence on PROs
than device-related factors.25,26 This is likely due to CHF symp-
toms having a significant influence on daily living incurring limita-
tions in both physical and social activities in addition to patients
with CHF having to adhere to a strict treatment regimen that
includes a combination of dietary restrictions, daily weighing and
the prescription of multiple drugs. The results of the current
study also suggest that the psychological well-being of CHF
patients is not necessarily negatively affected with the implantation
of an ICD, as ICD + CHF patients reported the lowest anxiety
level and the best mental health status as compared to CHF
only patients. Although ICD patients can experience more distress
at the time of implantation or shortly thereafter, due to restrictions
concerning physical exercise and driving, over time their well being
seems to improve and exceeds that of CHF patients. However,
again mean differences between groups were small, and the CHF
and ICD + CHF patients differed on CHF severity at baseline.
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Figure 2 (A) Mean anxiety scores, stratified by group (adjusted
analysis). Scores can range between 0 and 42 with a cut-off score
of ≥8 indicating clinically elevated anxiety. (B) Mean depression
scores, stratified by group (adjusted analysis). Scores can range
between 0 and 42 with a cut-off score of ≥8 indicating clinically
elevated depression.
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Table 2 Effect size (Cohen’s d)
ICD vs.
CHF
ICD vs.
ICD 1 CHF
CHF vs.
ICD 1 CHF
PCS
Baseline* 0.31 0.33 0.69
6 months 0.15 0.17 0.03
12 months 0.10 0.24 0.14
MCS
Baseline* 0.40 0.03 0.37
6 months* 0.50 0.16 0.61
12 months* 0.36 0.18 0.51
Anxiety
Baseline 0.09 0.03 0.06
12 months* 0.21 0.33 0.53
Depression
Baseline 0.02 0.23 0.20
12 months 0.15 0.05 0.19
Effect size: 0.2 ¼ small; 0.5 ¼ medium; 0.8 ¼ large.
*P, 0.05.
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For clinicians it is important to be aware of the negative influ-
ence of symptomatic heart disease on PROs, given that distress
and poor health status have been identified as risk markers for
both morbidity and mortality across different cardiac popula-
tions.27 –29 Clinicians should be careful not to overestimate the
impact of living with a device and being faced with ICD therapies
on PROs, as other factors such as symptomatic heart failure may
play an equally important or greater role. Patients reporting
poor PROs might benefit from additional support from medical
staff or mental health providers. Cognitive behavioural therapy
has also been shown to significantly reduce psychological distress
and improve health status in ICD patients.30,31
A number of limitations of this study must be acknowledged.
First, anxiety and depression were assessed using self-report ques-
tionnaires rather than clinical diagnostic interviews. However,
interviews are burdensome to patients, and there is evidence to
suggest that even minimal symptoms of depression predict poor
prognosis in cardiac patients.29 Second, 22% of patients refused
study participation, while another subset of patients were lost to
attrition during follow-up. However, patients excluded from ana-
lyses did not differ systematically on any of the study variables
from included patients, safeguarding the generalizability of the find-
ings to the total sample. Third, due to the inherent nature of the
study design we were not able to control for ICD shocks in multi-
variable analyses, as a subset of patients did not have an ICD.
However, ICD shocks have been shown only to explain a marginal
proportion of the variance in PROs and changes in PROs.3– 5
Fourth, the majority of CHF patients had a NYHA functional
class I or II indicating mild heart failure symptoms. This may have
been the reason why we did not find large differences between
groups. Fifth, patients in the CHF cohort were not included into
the study at the time of diagnosis but at a later time point.
However, by statistically controlling for NYHA class in multivari-
able analyses we sought to standardize for the potential effect
that this might have on our results. In addition the ICD + CHF
group was much smaller than the two other groups and the
groups differed on several baseline measures, as displayed in
Table 1. In adjusted analyses we have, however, controlled for
these differences by including those variables as covariates in the
model. Finally, a follow-up period of 12 months is relatively
short and replication of our findings over a longer period is war-
ranted. Replication of our findings in other countries is also war-
ranted as the management and care of patients might differ
across countries.
This study also has several strengths, including patients repre-
senting ‘real world’ patients, the use of a prospective study
design, and the comparison of the relative influence of underlying
heart disease and device placement on PROs.
In conclusion, the results of the current study show that patients
with an ICD do not necessarily report worse health status and
more symptoms of anxiety and depression as compared to
cardiac patients without a device, suggesting that ICD treatment
does not impact PROs more than symptomatic CHF (at 12
months follow-up). These results add to the current debate on
the impact of living with a device on patient well being,2 with
the results suggesting that living with symptomatic heart disease
rather than with a device impinges on PROs. For physicians
having to discuss the pros and cons of ICD implantation with
patients, it is important to have a true picture of the impact of
living with an ICD relative to heart disease on PROs.
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